欧洲杯竞猜

            1. Home
              Who We Are
              What We Do
              Corporate Responsibility
              News
              Careers
              Investors
              Patients and HCPS
              Contact us
              Careers | Investors | Patients and HCPS | Contact us
              Global
              中文站
              Careers Investors Patients and HCPS Contact us
              Overview
              Company Introduction

              Founded in 1998, Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH) is a pharmaceutical company in China, specializing in the development, production, and commercialization of insulin analogs and medical devices. Headquartered in Beijing, Gan & Lee has an industrial park of about 200,000 square meters. The company has more than 3,000 employees globally.

              Gan & Lee developed the first Chinese domestic insulin analog and currently has a series of insulin products approved in China. Moreover, Gan & Lee concluded a commercialization and supply agreement with Sandoz, a subsidiary of Novartis, to expand developed markets. As a global company focusing on the health of human beings, Gan & Lee is committed to providing scientific solutions to patients across the globe to have a positive impact on patient lives.
              Culture and Value

              欧洲杯竞猜的使命:欧洲杯竞猜的使命——为人类提供更高质量的药品和服务
              欧洲杯竞猜的愿景:欧洲杯竞猜的愿景——布局全球市场,成为世界顶尖的医药欧洲杯竞猜
              文化与宗旨:欧洲杯竞猜文化核心——科学 极致
                                 欧洲杯竞猜宗旨——质量第一 永远创新

              Our Vision

              To expand to a global market, all of the marketing, products, talent, and branding should have global aims. Gan and Lee is committed to becoming a trusted leader in the global pharmaceutical industry, and a leader in global reforms. The key to achieving this goal is the pursuit of innovative processes, business practices and products.

              Our Mission

              Gan & Lee's mission is to spread the culture of human health to all nations and people in the world, to solve challenging health problems facing society, to save the lives of patients, and to improve the quality of human life. We endeavor to provide patients, medical workers and the medical insurance system with more valuable treatment options and reduce the cost of treatment. We aim to improve global health by meeting high standards for our products and services that enable people to live healthier lives.

              Gan & Lee is committed to adopting sound product, processes, and quality to make reliable products. We also adhere to strict professional ethics and responsible working attitude to provide better services.

              Culture and Tenet

              Science leads our working approaches. Gan & Lee colleagues should be able to design the process, improve the methods, as well as judge the results from a scientific perspective, pursuing excellence.

              We are committed to adopting the advanced production standards to make reliable products, and never stop the advancement and exploratory pace in product development, technological innovation, and market development. Every milestone of progress provides Gan & Lee a valuable learning experience.

              To be a world-class pharmaceutical company with focus on global business development

              To provide high quality products and improve human lives globally

              Science & Excellence
              Quality First, Innovation Forever

              History

              Milestones

              MORE
              1998

              Founded R&D Center - Beijing Gan & Lee Biotechnology Co., Ltd. (later became Gan & Lee Pharmaceuticals)
              Completed the construction of the world's 3rd largest recombinant human insulin production base

              MORE
              2001

              Successfully developed China's 1st fast-acting human insulin analog - Prandilin (Lispro)

              MORE
              2002

              Successfully developed China's 1st long-acting human insulin analog - Basalin (Glargine)
              Successfully developed China's 1st premixed human insulin analog - Prandilin 25 (Lispro 25R)

              MORE
              2005

              Company was restructured and renamed to“Gan & Lee Pharmaceuticals Co., Ltd.”
              Patents were obtained for the Molecular Chaperone Technology in China and PCT patent was obtained in the US
              Received production approval and GMP certificate for Basalin from the NMPA (before CFDA)

              MORE
              2007

              Basalin went on sale

              MORE
              2008

              Basalin entered the international market, including Egypt, Pakistan, Mexico, etc.

              MORE
              2009

              The company's sales revenue exceeded RMB100 million
              China's 1st independently developed insulin injection pen-Insulin Pen was launched

              MORE
              2012

              The company completed the shareholding transformation and its name was changed to “Gan & Lee Pharmaceuticals”

              MORE
              2014

              China's 1st premixed human insulin analog Prandilin 25 was launched
              Founded Gan & Lee Pharmaceuticals USA

              MORE
              2015

              Completed the construction of the new insulin analog manufacturing plant in Beijing
              Insulin glargine was allowed by the FDA to proceed with Phase I clinical study in US

              MORE
              2018

              Basalin passed Europe's QP inspection and was allowed to proceed with Phase I and Phase III clinical trials in Europe
              Gan & Lee attended the 78th American Diabetes Annual Conference (ADA) as the first Chinese pharmaceuticals to attend the conference
              Gan & Lee concluded a commercialization and supply agreement with Sandoz, a subsidiary of Novartis on biosimilar versions of insulins used in patients with type 1 and type 2 diabetes

              MORE
              2019

              Recombinant insulin lispro was allowed by the FDA & European Medicines Agency to proceed with Phase I and Phase III clinical trials in the US and Europe

              MORE
              2020

              Gan & Lee was Initially listed on the A-share index on the Shanghai Stock Exchange
              Aspart was approved for listing in China
              Started the construction of Gan & Lee Linyi Production Base

              MORE
              2021

              Gan & Lee Announces New Partnership with the International Diabetes Federation
              EMA granted orphan drug designation for GLR2007
              The clinical trial application of GZR18, a GLP-1 RA, is approved by the Chinese National Medical Products Administration

              MORE
              Copyright 2021 Gan & Lee Pharmaceuticals Co Ltd . All Rights Reserved.
              Our websites

              Subscribe

              I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.

                  1. 欧洲杯竞猜